Related Experiment Video
Updated: Jun 28, 2026

14:23
A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
16.3K
Site-1 protease mediated GPC processing is required for persistence of LCMV Clone 13
Ruifeng Zhou1, Haydar Witwit1, Tingting Ai1
1Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Npj Viruses
|March 14, 2026
Summary
Mammarenaviruses uniquely use site-1 protease (S1P) for glycoprotein processing. Targeting S1P offers a novel antiviral strategy against these viruses, impacting their fitness and immune evasion.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Most enveloped viruses utilize furin for glycoprotein maturation.
- Mammarenaviruses uniquely depend on host site-1 protease (S1P) for glycoprotein precursor (GPC) processing.
- The biological significance of S1P reliance in mammarenaviruses is not well understood.
Purpose of the Study:
- To investigate the role of S1P-mediated GPC processing in mammarenavirus pathogenesis.
- To characterize a furin-dependent recombinant lymphocytic choriomeningitis virus (LCMV) variant.
- To evaluate S1P as a potential antiviral target.
Main Methods:
- Generation of a furin-dependent LCMV variant (rCl13-RRRR).
- In vitro cell culture fitness assays.
- In vivo pathogenesis and persistence studies in immunocompetent mice.
- Analysis of viral clearance mechanisms (interferon, CD8+ T cells).
- Assessment of protective immunity post-infection.
Main Results:
- The furin-dependent rCl13-RRRR showed comparable cell culture fitness to the wild-type rCl13.
- rCl13-RRRR was significantly attenuated in vivo, failing to establish persistent infection.
- Viral clearance required interferon and CD8+ T cell responses.
- Immunization with rCl13-RRRR provided protection against lethal LCMV challenge.
Conclusions:
- S1P-mediated GPC processing is critical for mammarenavirus in vivo fitness and immune evasion.
- This unique viral processing mechanism highlights S1P as a druggable target for antiviral therapies.
- Host-directed strategies targeting S1P could combat pathogenic mammarenaviruses.

